675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Announces Second Quarter 2025 Operating Results and Provides a Business Update
Material disclosure
Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
Announces First Quarter 2025 Operating Results and Provides a Business Update
Annual Report to Security Holders
Changes in Board, Management or Compensation
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Provides Business Update and Announces Interim Leadership Changes
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Confidential Treatment Order
Correspondence
Submission Upload